Literature DB >> 15948250

Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats.

Dong-Chang Zhao1, Jun-Xia Lei, Rui Chen, Wei-Hua Yu, Xiu-Ming Zhang, Shu-Nong Li, Peng Xiang.   

Abstract

AIM: Recent reports have shown the capacity of mesenchymal stem cells (MSCs) to differentiate into hepatocytes in vitro and in vivo. MSCs administration could repair injured liver, lung, or heart through reducing inflammation, collagen deposition, and remodeling. These results provide a clue to treatment of liver fibrosis. The aim of this study was to investigate the effect of infusion of bone marrow (BM)-derived MSCs on the experimental liver fibrosis in rats.
METHODS: MSCs isolated from BM in male Fischer 344 rats were infused to female Wistar rats induced with carbon tetrachloride (CCl4) or dimethylnitrosamine (DMN). There were two random groups on the 42nd d of CCl4:CCl4/MSCs, to infuse a dose of MSCs alone; CCl4/saline, to infuse the same volume of saline as control. There were another three random groups after exposure to DMN: DMN10/MSCs, to infuse the same dose of MSCs on d 10; DMN10/saline, to infuse the same volume of saline on d 10; DMN20/MSCs, to infuse the same dose of MSCs on d 20. The morphological and behavioral changes of rats were monitored everyday. After 4-6 wk of MSCs administration, all rats were killed and fibrosis index were assessed by histopathology and radioimmunoassay. Smooth muscle alpha-actin (alpha-SMA) of liver were tested by immunohistochemistry and quantified by IBAS 2.5 software. Male rats sex determination region on the Y chromosome (sry) gene were explored by PCR.
RESULTS: Compared to controls, infusion of MSCs reduced the mortality rates of incidence in CCl4-induced model (10% vs 20%) and in DMN-induced model (20-40% vs 90%). The amount of collagen deposition and alpha-SMA staining was about 40-50% lower in liver of rats with MSCs than that of rats without MSCs. The similar results were observed in fibrosis index. And the effect of the inhibition of fibrogenesis was greater in DMN10/MSCs than in DMN20/MSCs. The sry gene was positive in the liver of rats with MSCs treatment by PCR.
CONCLUSION: MSCs treatment can protect against experimental liver fibrosis in CCl4-induced or DMN-induced rats and the mechanisms of the anti-fibrosis by MSCs will be studied further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948250      PMCID: PMC4315999          DOI: 10.3748/wjg.v11.i22.3431

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates.

Authors:  Steven M Devine; Carrington Cobbs; Matt Jennings; Amelia Bartholomew; Ron Hoffman
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

2.  Pluripotency of mesenchymal stem cells derived from adult marrow.

Authors:  Yuehua Jiang; Balkrishna N Jahagirdar; R Lee Reinhardt; Robert E Schwartz; C Dirk Keene; Xilma R Ortiz-Gonzalez; Morayma Reyes; Todd Lenvik; Troy Lund; Mark Blackstad; Jingbo Du; Sara Aldrich; Aaron Lisberg; Walter C Low; David A Largaespada; Catherine M Verfaillie
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

Review 3.  Mesenchymal stem cells: paradoxes of passaging.

Authors:  Elisabeth H Javazon; Kirstin J Beggs; Alan W Flake
Journal:  Exp Hematol       Date:  2004-05       Impact factor: 3.084

4.  In vitro hepatic differentiation of human mesenchymal stem cells.

Authors:  Kuan-Der Lee; Tom Kwang-Chun Kuo; Jacqueline Whang-Peng; Yu-Fen Chung; Ching-Tai Lin; Shiu-Huey Chou; Jim-Ray Chen; Yi-Peng Chen; Oscar Kuang-Sheng Lee
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

5.  Hepatocyte growth factor gene therapy of liver cirrhosis in rats.

Authors:  T Ueki; Y Kaneda; H Tsutsui; K Nakanishi; Y Sawa; R Morishita; K Matsumoto; T Nakamura; H Takahashi; E Okamoto; J Fujimoto
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

6.  Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats.

Authors:  T Nakamura; R Sakata; T Ueno; M Sata; H Ueno
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

7.  Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation.

Authors:  N Trim; S Morgan; M Evans; R Issa; D Fine; S Afford; B Wilkins; J Iredale
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

8.  Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats.

Authors:  Christopher J Parsons; Blair U Bradford; Clark Q Pan; Ellen Cheung; Michael Schauer; Andreas Knorr; Barbara Krebs; Sabine Kraft; Stefan Zahn; Bodo Brocks; Nikki Feirt; Baisong Mei; Myung-Sam Cho; Roopa Ramamoorthi; Greg Roldan; Paul Ng; Peggy Lum; Claudia Hirth-Dietrich; Adrian Tomkinson; David A Brenner
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

9.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.

Authors:  J P Iredale; R C Benyon; J Pickering; M McCullen; M Northrop; S Pawley; C Hovell; M J Arthur
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

10.  Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.

Authors:  Luis A Ortiz; Frederica Gambelli; Christine McBride; Dina Gaupp; Melody Baddoo; Naftali Kaminski; Donald G Phinney
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

View more
  92 in total

1.  Modulation of AP-endonuclease1 levels associated with hepatic cirrhosis in rat model treated with human umbilical cord blood mononuclear stem cells.

Authors:  Ahmad R Bassiouny; Amira Z Zaky; Shaymaa A Abdulmalek; Kamal M Kandeel; Alaa Ismail; Marie Moftah
Journal:  Int J Clin Exp Pathol       Date:  2011-10-16

Review 2.  Stem Cell Therapy: Current Applications and Potential for Urology.

Authors:  Bridget Wiafe; Peter D Metcalfe; Adetola B Adesida
Journal:  Curr Urol Rep       Date:  2015-11       Impact factor: 3.092

3.  The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.

Authors:  Yu-Pei Fan; Ching-Chih Hsia; Kuang-Wen Tseng; Chih-Kai Liao; Tz-Win Fu; Tsui-Ling Ko; Mei-Miao Chiu; Yang-Hsin Shih; Pei-Yu Huang; Yi-Chia Chiang; Chih-Ching Yang; Yu-Show Fu
Journal:  Stem Cells Transl Med       Date:  2015-12-30       Impact factor: 6.940

Review 4.  Stem cells for liver tissue repair: current knowledge and perspectives.

Authors:  Philippe A Lysy; David Campard; Françoise Smets; Mustapha Najimi; Etienne M Sokal
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

Review 5.  Stem cells for end stage liver disease: how far have we got?

Authors:  Stefania Lorenzini; Stefano Gitto; Elena Grandini; Pietro Andreone; Mauro Bernardi
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

6.  Reversal of Hepatic Fibrosis by Human CD34(+) Stem/Progenitor Cell Transplantation in Rats.

Authors:  M T Abdel Aziz; Mf El Asmar; S Mostafa; H Salama; H M Atta; S Mahfouz; N K Roshdy; L A Rashed; D Sabry; N Hasan; M Mahmoud; D Elderwy
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

7.  Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells.

Authors:  Biju Parekkadan; Daan van Poll; Zaki Megeed; Naoya Kobayashi; Arno W Tilles; François Berthiaume; Martin L Yarmush
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

Review 8.  Cellular therapy for liver disease.

Authors:  Robert C Huebert; Jorge Rakela
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

9.  Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury.

Authors:  Florian Tögel; Arthur Cohen; Ping Zhang; Ying Yang; Zhuma Hu; Christof Westenfelder
Journal:  Stem Cells Dev       Date:  2009-04       Impact factor: 3.272

10.  Therapy with bone marrow cells reduces liver alterations in mice chronically infected by Schistosoma mansoni.

Authors:  Sheilla Andrade Oliveira; Bruno-Solano-Freitas Souza; Carla-Adriana Guimaraes-Ferreira; Elton-Sa Barreto; Siane-Campos Souza; Luiz-Antonio-Rodrigues Freitas; Ricardo Ribeiro-Dos-Santos; Milena-Botelho-Pereira Soares
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.